Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.

[1]  M. Olfson,et al.  National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. , 2012, Archives of general psychiatry.

[2]  J. Alda,et al.  Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: design of a follow-up protocol and baseline results. , 2012 .

[3]  B. Vandermeer,et al.  Antipsychotics for Children and Young Adults: A Comparative Effectiveness Review , 2012, Pediatrics.

[4]  Marc De Hert,et al.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs , 2012, Nature Reviews Endocrinology.

[5]  D. Safer.  Age-grouped differences in adverse drug events from psychotropic medication. , 2011, Journal of child and adolescent psychopharmacology.

[6]  A. Zuddas,et al.  Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies , 2011, European Neuropsychopharmacology.

[7]  Carmen Moreno,et al.  Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons , 2011, European Neuropsychopharmacology.

[8]  A. Rudich,et al.  Adolescent BMI trajectory and risk of diabetes versus coronary disease. , 2011, The New England journal of medicine.

[9]  C. Panagiotopoulos,et al.  First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. , 2010, Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent.

[10]  J. Alda,et al.  Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. , 2010, Bipolar disorders.

[11]  N. Andreasen,et al.  Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs , 2010, Biological Psychiatry.

[12]  J. McClellan,et al.  Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. , 2009, JAMA.

[13]  A. Malhotra,et al.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. , 2009, JAMA.

[14]  Alessandro Zuddas,et al.  Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns , 2009, European Neuropsychopharmacology.

[15]  C. Arango,et al.  Olanzapine compared to quetiapine in adolescents with a first psychotic episode , 2009, European Child & Adolescent Psychiatry.

[16]  Ann E. Maloney,et al.  Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. , 2008, The American journal of psychiatry.

[17]  Benjamin Caballero,et al.  Will All Americans Become Overweight or Obese? Estimating the Progression and Cost of the US Obesity Epidemic , 2008, Obesity.

[18]  C. Arango,et al.  Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. , 2008, The Journal of clinical psychiatry.

[19]  C. Glueck,et al.  Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. , 2008, The Journal of pediatrics.

[20]  J. P. L. Siguero,et al.  Prevalencia del sndrome metablico y sus componentes en nios y adolescentes con obesidad , 2007 .

[21]  J. D. Serra,et al.  ASOCIACIÓN ESPAÑOLA DE PEDIATRÍA Obesidad Infantil. Recomendaciones del Comité de Nutrición de la Asociación Española de Pediatría. Parte II. Diagnóstico. Comorbilidades. Tratamiento , 2007 .

[22]  J. Bobes,et al.  Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study , 2007, Schizophrenia Research.

[23]  C. Correll,et al.  Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[24]  M. Olfson,et al.  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. , 2006, Archives of general psychiatry.

[25]  O. Raitakari,et al.  Obesity in youth is not an independent predictor of carotid IMT in adulthood. The Cardiovascular Risk in Young Finns Study. , 2006, Atherosclerosis.

[26]  C. Correll,et al.  Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. , 2005, The American journal of psychiatry.

[27]  K. Widhalm,et al.  New insights into the field of children and adolescents’ obesity: the European perspective , 2004, International Journal of Obesity.

[28]  B. Rosner,et al.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents , 2004 .

[29]  J. Racoosin,et al.  Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. , 2004, Diabetes care.

[30]  Clive Osmond,et al.  Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. , 2004, The New England journal of medicine.

[31]  T. Laitinen,et al.  Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. , 2003, JAMA.

[32]  W. Dietz,et al.  Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of pediatrics & adolescent medicine.

[33]  R J Prineas,et al.  Relation of weight and rate of increase in weight during childhood and adolescence to body size, blood pressure, fasting insulin, and lipids in young adults. The Minneapolis Children's Blood Pressure Study. , 1999, Circulation.

[34]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[35]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[36]  C. McDougle,et al.  Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[37]  C. Correll.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. , 2008, Journal of the American Academy of Child and Adolescent Psychiatry.

[38]  R. Huupponen,et al.  The Cardiovascular Risk in Young Finns Study , 2008 .

[39]  A. Malhotra,et al.  Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. , 2006, Child and adolescent psychiatric clinics of North America.